Syros Pharmaceuticals Stock Forecast, Price & News

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view top-rated stocks.

How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have decreased by 54.0% and is now trading at $2.37.
View which stocks have been most impacted by COVID-19.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Friday, November, 5th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.03. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 77.65% and a negative net margin of 434.32%. During the same period last year, the firm earned ($0.43) EPS.
View Syros Pharmaceuticals' earnings history.

What price target have analysts set for SYRS?

3 equities research analysts have issued 1-year price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $23.00. On average, they expect Syros Pharmaceuticals' stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 592.0% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:

• Nancy A. Simonian, President, Chief Executive Officer & Director
• Gerald E. Quirk, Chief Operating Officer
• Jason Haas, Chief Financial Officer
• Eric R. Olson, Chief Scientific Officer
• David A. Roth, Chief Medical Officer

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Syros Pharmaceuticals' key competitors?

Some companies that are related to Syros Pharmaceuticals include Pharvaris (PHVS), Zymeworks (ZYME), Kinnate Biopharma (KNTE), Mirum Pharmaceuticals (MIRM), Kronos Bio (KRON), LianBio (LIAN), Intercept Pharmaceuticals (ICPT), Fulcrum Therapeutics (FULC), Albireo Pharma (ALBO), Lexicon Pharmaceuticals (LXRX), BioXcel Therapeutics (BTAI), Relmada Therapeutics (RLMD), POINT Biopharma Global (PNT), Inventiva (IVA) and Chimerix (CMRX).
View all of SYRS's competitors.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LGT Capital Partners LTD. (0.81%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends for Syros Pharmaceuticals.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was purchased by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD..
View insider buying and selling activity for Syros Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $2.37.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $146.81 million and generates $15.09 million in revenue each year. The company earns $-84.04 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 103 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 744-1340 or via email at [email protected].